Summary
Heron Therapeutics, Inc. (HRTX) Q3 2025 Earnings Call Transcript
Heron Therapeutics, Inc. ( HRTX ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Melissa Jarel - Executive Director of Legal Craig Collard - CEO & Director Mark Hensley - Executive VP & COO Ira Duarte - Executive VP & CFO Kevin Warner - Senior Vice President of Medical Affairs Strategy & Engagement William Forbes - Executive VP & Chief Development Officer Conference Call Participants Carl Byrnes - Northland Capital Markets, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Presentation Operator Good day, and thank you for standing by.
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.03 per share a year ago.
Heron Therapeutics Inc. (AXD2) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Heron Therapeutics Inc. ever had a stock split?
Heron Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Craig Alexander Collard CEO | XBER Exchange | US4277461020 ISIN |
| US Country | 122 Employees | - Last Dividend | 13 Jan 2014 Last Split | 26 Aug 1987 IPO Date |
Overview
Heron Therapeutics, Inc. is a commercial-stage biotechnology firm committed to improving patient lives through the development and commercialization of innovative therapeutics that enhance medical care. The company leverages its proprietary Biochronomer drug delivery technology to provide sustained therapeutic levels of various short-acting pharmacological agents over days to weeks with a single administration. Originating as A.P. Pharma, Inc., the corporation transitioned to Heron Therapeutics, Inc. in January 2014. Founded in 1983, it is based in San Diego, California. This technology underscores Heron's dedication to addressing unmet medical needs by optimizing drug delivery for better efficacy and patient convenience.
Products and Services
- SUSTOL (granisetron)
As an extended-release injection, SUSTOL is designed to prevent both acute and delayed nausea and vomiting that can occur following moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide combination chemotherapy regimens. Its formulation allows for sustained release, aiming to improve patient comfort and treatment adherence.
- CINVANTI (aprepitant)
CINVANTI is an intravenous formulation of aprepitant, acting as a substance P/neurokinin-1 (NK1) receptor antagonist. It is indicated for the prevention of both acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting caused by moderately emetogenic cancer chemotherapy. This product highlights the company's focus on enhancing post-chemotherapy care.
- ZYNRELEF
This dual-acting local anesthetic offers a fixed-dose combination of bupivacaine and meloxicam, a local anesthetic and a nonsteroidal anti-inflammatory drug (NSAID), respectively. ZYNRELEF is developed for the delivery of prolonged pain relief, showcasing Heron's initiative in improving post-operative care through innovative pharmaceutical approaches.
- APONVIE (intravenous formulation)
APONVIE is intended for the prevention of postoperative nausea and vomiting (PONV) in adults. As an intravenous formulation of a substance P/neurokinin-1 receptor antagonist, it signifies the company’s commitment to advancing recovery care and enhancing the postoperative experience for patients.
Contact Information
